Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance.

Santoni-Rugiu E, Melchior LC, Urbanska EM, Jakobsen JN, Stricker K, Grauslund M, Sørensen JB.

Cancers (Basel). 2019 Jul 1;11(7). pii: E923. doi: 10.3390/cancers11070923. Review.

2.

Introduction.

Grauslund M, Scheie D, Moser C.

APMIS. 2019 May;127(5):239. doi: 10.1111/apm.12952. No abstract available.

PMID:
30985019
3.

Biomarkers in tumors of the central nervous system - a review.

Scheie D, Kufaishi HHA, Broholm H, Lund EL, de Stricker K, Melchior LC, Grauslund M.

APMIS. 2019 May;127(5):265-287. doi: 10.1111/apm.12916. Epub 2019 Feb 10. Review.

PMID:
30740783
4.

Genomic alterations accompanying tumour evolution in colorectal cancer: tracking the differences between primary tumours and synchronous liver metastases by whole-exome sequencing.

Mogensen MB, Rossing M, Østrup O, Larsen PN, Heiberg Engel PJ, Jørgensen LN, Hogdall EV, Eriksen J, Ibsen P, Jess P, Grauslund M, Nielsen HJ, Nielsen FC, Vainer B, Osterlind K.

BMC Cancer. 2018 Jul 20;18(1):752. doi: 10.1186/s12885-018-4639-4.

5.

Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment.

Jakobsen JN, Santoni-Rugiu E, Grauslund M, Melchior L, Sørensen JB.

Oncotarget. 2018 May 25;9(40):26195-26208. doi: 10.18632/oncotarget.25490. eCollection 2018 May 25.

6.

The PRKD1 E710D hotspot mutation is highly specific in separating polymorphous adenocarcinoma of the palate from adenoid cystic carcinoma and pleomorphic adenoma on FNA.

Andreasen S, Melchior LC, Kiss K, Bishop JA, Høgdall E, Grauslund M, Wessel I, Homøe P, Agander TK.

Cancer Cytopathol. 2018 Apr;126(4):275-281. doi: 10.1002/cncy.21959. Epub 2017 Dec 20.

7.

Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.

Santoni-Rugiu E, Grauslund M, Melchior LC, Costa JC, Sørensen JB, Urbanska EM.

Lung Cancer. 2017 Nov;113:14-17. doi: 10.1016/j.lungcan.2017.08.024. Epub 2017 Sep 1.

8.

Lacrimal gland ductal carcinomas: Clinical, Morphological and Genetic characterization and implications for targeted treatment.

Andreasen S, Grauslund M, Heegaard S.

Acta Ophthalmol. 2017 May;95(3):299-306. doi: 10.1111/aos.13310. Epub 2016 Nov 3.

9.

Multi-Center Evaluation of the Fully Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal Cancer.

Solassol J, Vendrell J, Märkl B, Haas C, Bellosillo B, Montagut C, Smith M, O'Sullivan B, D'Haene N, Le Mercier M, Grauslund M, Melchior LC, Burt E, Cotter F, Stieber D, Schmitt FL, Motta V, Lauricella C, Colling R, Soilleux E, Fassan M, Mescoli C, Collin C, Pagès JC, Sillekens P.

PLoS One. 2016 Sep 29;11(9):e0163444. doi: 10.1371/journal.pone.0163444. eCollection 2016.

10.

The interleukin-6/Janus kinase/STAT3 pathway in pleomorphic adenoma and carcinoma ex pleomorphic adenoma of the lacrimal gland.

Andreasen S, Heegaard S, Grauslund M, Homøe P.

Acta Ophthalmol. 2016 Dec;94(8):798-804. doi: 10.1111/aos.13122. Epub 2016 Jun 11.

11.

Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma.

Andersen M, Trapani D, Ravn J, Sørensen JB, Andersen CB, Grauslund M, Santoni-Rugiu E.

Anticancer Res. 2015 Nov;35(11):6223-9.

PMID:
26504055
12.

Multi-center evaluation of the novel fully-automated PCR-based Idylla™ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma.

Melchior L, Grauslund M, Bellosillo B, Montagut C, Torres E, Moragón E, Micalessi I, Frans J, Noten V, Bourgain C, Vriesema R, van der Geize R, Cokelaere K, Vercooren N, Crul K, Rüdiger T, Buchmüller D, Reijans M, Jans C.

Exp Mol Pathol. 2015 Dec;99(3):485-91. doi: 10.1016/j.yexmp.2015.09.004. Epub 2015 Sep 25.

PMID:
26407762
13.

Activation of the interleukin-6/Janus kinase/STAT3 pathway in pleomorphic adenoma of the parotid gland.

Andreasen S, Therkildsen MH, Grauslund M, Friis-Hansen L, Wessel I, Homøe P.

APMIS. 2015 Aug;123(8):706-15. doi: 10.1111/apm.12407. Epub 2015 Jun 8.

PMID:
26061266
14.

Medullary carcinoma of the colon: can the undifferentiated be differentiated?

Fiehn AM, Grauslund M, Glenthøj A, Melchior LC, Vainer B, Willemoe GL.

Virchows Arch. 2015 Jan;466(1):13-20. doi: 10.1007/s00428-014-1675-6. Epub 2014 Oct 23.

PMID:
25339302
15.

Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma.

Andersen M, Grauslund M, Ravn J, Sørensen JB, Andersen CB, Santoni-Rugiu E.

J Mol Diagn. 2014 Jul;16(4):418-30. doi: 10.1016/j.jmoldx.2014.03.002. Epub 2014 Jun 6.

16.
17.

Ovarian tissue cryopreserved for fertility preservation from patients with Ewing or other sarcomas appear to have no tumour cell contamination.

Greve T, Wielenga VT, Grauslund M, Sørensen N, Christiansen DB, Rosendahl M, Yding Andersen C.

Eur J Cancer. 2013 May;49(8):1932-8. doi: 10.1016/j.ejca.2013.01.032. Epub 2013 Feb 26.

PMID:
23452988
18.

Are differentially expressed microRNAs useful in the diagnostics of malignant pleural mesothelioma?

Andersen M, Grauslund M, Muhammad-Ali M, Ravn J, Sørensen JB, Andersen CB, Santoni-Rugiu E.

APMIS. 2012 Sep;120(9):767-9. doi: 10.1111/j.1600-0463.2012.02891.x. Epub 2012 Mar 5. No abstract available.

PMID:
22882267
19.

PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.

Jensen JD, Knoop A, Laenkholm AV, Grauslund M, Jensen MB, Santoni-Rugiu E, Andersson M, Ewertz M.

Ann Oncol. 2012 Aug;23(8):2034-42. doi: 10.1093/annonc/mdr546. Epub 2011 Dec 15.

20.

Proteomic profiling of human colon cancer cells treated with the histone deacetylase inhibitor belinostat.

Beck HC, Petersen J, Nielsen SJ, Morsczeck C, Jensen PB, Sehested M, Grauslund M.

Electrophoresis. 2010 Aug;31(16):2714-21. doi: 10.1002/elps.201000033. Erratum in: Electrophoresis. 2010 Oct;31(21):3619. Morszeck, Christian [corrected to Morsczeck, Christian].

PMID:
20717991
21.

A murine experimental anthracycline extravasation model: pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damage.

Thougaard AV, Langer SW, Hainau B, Grauslund M, Juhl BR, Jensen PB, Sehested M.

Toxicology. 2010 Feb 28;269(1):67-72. doi: 10.1016/j.tox.2010.01.007. Epub 2010 Jan 15.

PMID:
20079798
22.

Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.

Martin E, Thougaard AV, Grauslund M, Jensen PB, Bjorkling F, Hasinoff BB, Tjørnelund J, Sehested M, Jensen LH.

Toxicology. 2009 Jan 8;255(1-2):72-9. doi: 10.1016/j.tox.2008.10.011. Epub 2008 Oct 25.

PMID:
19010377
23.

Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.

Dejligbjerg M, Grauslund M, Litman T, Collins L, Qian X, Jeffers M, Lichenstein H, Jensen PB, Sehested M.

Mol Cancer. 2008 Sep 12;7:70. doi: 10.1186/1476-4598-7-70.

24.

Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines.

Dejligbjerg M, Grauslund M, Christensen IJ, Tjørnelund J, Buhl Jensen P, Sehested M.

Cancer Biomark. 2008;4(2):101-9.

PMID:
18503161
25.

A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase IIalpha in vivo.

Grauslund M, Thougaard AV, Füchtbauer A, Hofland KF, Hjorth PH, Jensen PB, Sehested M, Füchtbauer EM, Jensen LH.

Mol Pharmacol. 2007 Oct;72(4):1003-14. Epub 2007 Jul 10.

PMID:
17622580
26.
27.

Quantitative proteomic analysis of post-translational modifications of human histones.

Beck HC, Nielsen EC, Matthiesen R, Jensen LH, Sehested M, Finn P, Grauslund M, Hansen AM, Jensen ON.

Mol Cell Proteomics. 2006 Jul;5(7):1314-25. Epub 2006 Apr 20.

28.

Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors.

Jensen LH, Thougaard AV, Grauslund M, Søkilde B, Carstensen EV, Dvinge HK, Scudiero DA, Jensen PB, Shoemaker RH, Sehested M.

Cancer Res. 2005 Aug 15;65(16):7470-7.

29.

Separation of bisdioxopiperazine- and vanadate resistance in topoisomerase II.

Sorensen TK, Grauslund M, Jensen PB, Sehested M, Jensen LH.

Biochem Biophys Res Commun. 2005 Sep 2;334(3):853-60.

PMID:
16053917
30.
31.

ADAM12/syndecan-4 signaling promotes beta 1 integrin-dependent cell spreading through protein kinase Calpha and RhoA.

Thodeti CK, Albrechtsen R, Grauslund M, Asmar M, Larsson C, Takada Y, Mercurio AM, Couchman JR, Wewer UM.

J Biol Chem. 2003 Mar 14;278(11):9576-84. Epub 2002 Dec 31.

34.

Amino acids induce expression of BAP2, a branched-chain amino acid permease gene in Saccharomyces cerevisiae.

Didion T, Grauslund M, Kielland-Brandt MC, Andersen HA.

J Bacteriol. 1996 Apr;178(7):2025-9.

35.

Import of branched-chain amino acids in Saccharomyces cerevisiae.

Didion T, Grauslund M, Kielland-Brandt MC, Andersen HA.

Folia Microbiol (Praha). 1996;41(1):87. No abstract available.

PMID:
9090831
36.

BAP2, a gene encoding a permease for branched-chain amino acids in Saccharomyces cerevisiae.

Grauslund M, Didion T, Kielland-Brandt MC, Andersen HA.

Biochim Biophys Acta. 1995 Nov 30;1269(3):275-80.

Supplemental Content

Loading ...
Support Center